Sanofi-aventis Announces 2007 Earnings Ahead of Guidance Sharp Rise in Propose...(s with the ratio of selling and ge...),Health

selling and general expenses down 1.4 points at 26.9%

-- Earnings ahead of full-year guidance(4):

-- Business development highlights: signature of alliance agreements with

Regeneron, Acambis, Crucell and Oxford Biomedica, and buyout of rights

to several of our products in Japan

Share repurchase program and dividend

-- 29.4 million shares repurchased in 2007 for a total of euro 1.8 billion

-- A dividend increase of 18.3% to euro 2.07 per share proposed to the

Shareholders' Annual General Meeting

2008 guidance

Barring major adverse events, sanofi-aventis expects 2008 adjusted EPS excluding selected items(5) to grow around 7%, calculated at constant 2007 euro/dollar parity (1,371). Sensitivity to the euro/dollar exchange rate is estimated at 0.5% of growth for a 1-cent movement in the exchange rate. (see page 11)

(1) See Appendix 1 for a definition of financial indicators, and Appendix

6 for a description of selected items

(2) U.S. dollar figures obtained by translating euro-denominated figures

at the average exchange rate for the period: 1.449 for Q4 2007 (1.290

for Q4 2006) and 1.371 for FY 2007 (1.256 for FY 2006)

(3) Excluding net sales of Ambien(R) IR in the United States (from April)

and net sales of Eloxatin(R) in Europe

(4) Adjusted EPS excluding selected items up 13% at a constant 2006

euro/dollar rate (1.25) against guidance of 10% growth

(5) Adjusted EPS excluding selected items for 2007 was euro 5.17.

2007 fourth-quarter and full-year net sales
Unless otherwise indicated, all sales growth figures in this press release are

stated on a comparable basis(1). Sanofi-aventis generated fourth-quarter net sales of euro 6,911 million, down 2.2%. Exchange rate movements had an unfavorable effect of 4.2 points, mainly due to t
'/>"/>